Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice

Psychopharmacology

Volumn 183, Issue 4, 2006, Pages 490-499

  Wang, Jun Sheng ^a   DeVane, C Lindsay ^a,c   Gibson, B Bryan ^a   Donovan, Jennifer L ^a   Markowitz, John S ^b   Zhu, Hao Jie ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Blood brain barrier; Bupropion; Cytochrome P450; P glycoprotein; Risperidone; Sertraline

Indexed keywords

AMFEBUTAMONE; CYTOCHROME P450 2D6; DRUG METABOLIZING ENZYME; GLYCOPROTEIN P; NEUROLEPTIC AGENT; NORSERTRALINE; PALIPERIDONE; RISPERIDONE; SERTRALINE;

AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ALGORITHMS; ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BIOTRANSFORMATION; BRAIN; BUPROPION; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; MALE; MICE; P-GLYCOPROTEIN; POPULATION; RISPERIDONE; SEROTONIN ANTAGONISTS; SERTRALINE;

EID: 28344444695     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-005-0209-y     Document Type: Article

References (39)

1. Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, Beauclair L (2002) Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia. J Clin Psychopharmacol 22:20-25
2. Aguilar MA, Rodriguez-Arias M, Mari-Sanmillan MI, Minarro J (1997) Effects of risperidone on conditioned avoidance responding in male mice. Behav Pharmacol 8:669-876
3. Alfaro CL, Lam YW, Simpson J, Ereshefsky L (2000) CYP2D6 inhibition by fluoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J Clin Pharmacol 40:58-66
4. Bogaards JJ, Bertrand M, Jackson P, Oudshoorn MJ, Weaver RJ, van Bladeren PJ, Walther B (2000) Determining the best animal model for human cytochrome P450 activities: a comparison of mouse, rat, rabbit, dog, micropig, monkey and man. Xenobiotica 30:1131-1152
5. Boulton DW, DeVane CL, Liston HL, and Markowitz JS (2002) Human recombinant P-glycoprotein specificity for atypical antipsychotics. Life Sci 71:163-169
6. Bourin M, Colombel MC, Redrobe JP, Nizard J, Hascoet M, Baker GB (1998) Evaluation of efficacies of different classes of antidepressants in the forced swimming test in mice at different ages. Prog Neuropsychopharmacol Biol Psychiatry 22:343-351
7. Cooper TB, Suckow RF, Glassman A (1984) Determination of bupropion and its major basic metabolites in plasma by liquid chromatography with dual-wavelength ultraviolet detection. J Pharm Sci 73:1104-1107
8. Coryell W (1996) Psychotic depression. J Clin Psychiatry 57 (Suppl 3):27-31
9. Cox DS, Scott KR, Gao H, Eddington ND (2002) Effect of P-glycoprotein on the pharmacokinetics and tissue distribution of enaminone anticonvulsants: analysis by population and physiological approaches. J Pharmacol Exp Ther 302:1096-1104
10. DeVane CL (1998) Translational pharmacokinetics: current issues with newer antidepressants. Depress Anxiety 8 (Suppl 1):64-70
11. DeVane CL, Liston HL, Markowitz JS (2002) Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 41:1247-1266
12. Dodd S, Stocky A, Buist A, Burrows GD, Maguire K, Norman TR (2000) Sertraline in paired blood plasma and breast-milk samples from nursing mothers. Hum Psychopharmacol 15:161-264
13. Eap CB, Bondolfi G, Zullino D, Bryois C, Fuciec M, Savary L, Jonzier-Perey M, Baumann P (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Ther Drug Monit 23:228-231
14. Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn Schmiedebergs Arch Pharmacol 359:147-151
15. Guzey C, Norstrom A, Spigset O (2002) Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment with bupropion. Ther Drug Monit 24:436-437
16. He H, Richardson JS (1995) A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol 10:19-30
17. Hermann RC, Yang D, Ettner SL et al (2002) Prescription of antipsychotic drugs by office-based physicians in the United Sates, 1989-1997. Psychiatr Serv 53:425-430
18. Hesse LM, Venkatakrishnan K, Court MH, von Moltke LL, Duan SX, Shader RI, Greenblatt DJ (2000) CYP2B6 mediates the in vitro hydroxylation of bupropion: potential drug interactions with other antidepressants. Drug Metab Dispos 28:1176-1183
19. Karow A, Lambert M (2003) Polypharmacy in treatment with psychotropic drugs: the underestimated phenomenon. Curr Opin Psychiatry 16:713-718
20. Kobayashi K, Ishizuka T, Shimada N, Yoshimura Y, Kamijima K, Chiba K (1999) Sertraline N-demethylation is catalyzed by multiple isoforms of human cytochrome P-450 in vitro. Drug Metab Dispos 27:763-766
21. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, Adson DE (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226-229
22. Kurt M, Arik AC, Celik S (2000) The effects of sertraline and fluoxetine on anxiety in the elevated plus-maze test in mice. J Basic Clin Physiol Pharmacol 11:173-180
23. Laizure SC, DeVane CL (1985) Stability of bupropion and its major metabolites in human plasma. Ther Drug Monit 7:447-450
24. Lane RM (1996) Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 11 (Suppl 5):31-61
25. Liston HL, DeVane CL, Boulton DW, Risch SC, Markowitz JS, Goldman J (2002) Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 22:169-173
26. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ, Adkison KK, Polli JW (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303:1029-1037
27. Mauri MC, Laini V, Cerveri G, Scalvini ME, Volonteri LS, Regispani F, Malvini L, Manfre S, Boscati L, Panza G (2002) Clinical outcome and tolerability of sertraline in major depression: a study with plasma levels. Prog Neuropsychopharmacol Biol Psychiatry 26:597-601
28. Obach RS, Cox LM, Tremaine LM (2005) Sertraline is metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 33:262-270
29. Pirraglia PA, Stafford RS, Singer DE (2003) Trends in prescribing of selective serotonin reuptake inhibitors and other newer antidepressant agents in adult primary care. Prim Care Companion J Clin Psychiat 5:153-157
30. Pollock BG, Sweet RA, Kirshner M, Reynolds CF 3rd (1996) Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 18:581-585
31. Ronfeld RA, Tremaine LM, Wilner KD (1997) Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 32 (Suppl 1):22-30
32. Shad MU, Preskorn SH (1997) A possible bupropion and imipramine interaction. J Clin Psychopharmacol 17:118-119
33. Shin JG, Soukhova N, Flockhart DA (1999) Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27:1078-1084
34. Spina E, Scordo MG, D'Arrigo C (2003) Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol 17:517-538
35. Spina E, D'Arrigo C, Migliardi G, Morgante L, Zoccali R, Ancione M, Madia A (2004) Plasma risperidone concentrations during combined treatment with sertraline. Ther Drug Monit 26:386-390
36. Tohen M, Vieta E, Calabrese J et al (2003) Efficacy of olanzapine and olanzapine-bluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 60:1079-1088
37. Wang JS, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL (2004a) The brain entry of risperidone and 9-hydroxyrisperidone are greatly limited by P-glycoprotein. Int J Neuropsychopharmacol 7:415-419
38. Wang JS, Taylor R, Ruan Y, Donovan JL, Markowitz JS, DeVane CL (2004b) Olanzapine penetration into brain is greater in transgenic Abcb 1a P-glycoprotein deficient mice than FVB1 (wild-type) animals. Neuropsychopharmacology 29:551-557
39. Weiss J, Dormann SM, Martin-Facklam M, Kerpen CJ, Ketabi-Kiyanvash N, Haefeli WE (2003) Inhibition of P-glycoprotein by newer antidepressants. J Pharmacol Exp Ther 305:197-204